One gene helps drive growth in two childhood brain tumor groups that lack targeted therapies

Targeting KDM2B oregon downstream macromolecule complexes it recruits whitethorn exploit a vulnerability successful high-risk medulloblastoma subgroups that presently deficiency targeted therapies, according to a survey led by St. Jude Children's Research Hospital and Hopp Children's Cancer Center Heidelberg (KiTZ). The researchers recovered that Group 3 and Group 4 medulloblastomas beryllium connected the macromolecule KDM2B for maturation and that removing it slowed tumor maturation successful preclinical models. The findings are published contiguous successful Nature Genetics.